These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38924122)

  • 1. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
    Jewell RC; Mills RJ; Farrell C; Visser SAG
    Br J Clin Pharmacol; 2024 Oct; 90(10):2571-2581. PubMed ID: 38924122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
    Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
    Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
    Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
    Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
    Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
    Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
    Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
    Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
    Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
    Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
    Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
    Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.